art-i02
Gene therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2017 (NCT02727764)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-6Supplementation
IL6 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- art-i02
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03445715 | Phase 1 | Jan 3, 2018 | Arthrogen, University of Calgary |
| NCT02727764 | Phase 1 | Jul 1, 2017 | Arthrogen |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arthrogen | For profit | 2 | 2 | 1 | 2017 |
| University of Calgary | Academic/Hospital | 1 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1